NCT01563302 - Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 27, 2012

Primary Completion Date

March 23, 2016

Study Completion Date

March 23, 2016

Conditions

Advanced CancersDLBCLLymphoma

Interventions

DRUG

IONIS-STAT3Rx

Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.

Trial Locations (9)

Blood and Marrow Transplant Group of Georgia at Northside Hospital, Atlanta

Mayo Clinic, Rochester

Northwestern University, Chicago

Washington University School of Medicine, St Louis

Mary Crowley Cancer Research Centers, Dallas

MD Anderson Cancer Center, Houston

Mayo Clinic Arizona, Scottsdale

Moores UC San Diego Cancer Center, La Jolla

Yale Cancer Center, New Haven